tiprankstipranks
Compass Therapeutics initiated with a Buy at D. Boral Capital
The Fly

Compass Therapeutics initiated with a Buy at D. Boral Capital

D. Boral Capital initiated coverage of Compass Therapeutics (CMPX) with a Buy rating and $32 price target The clinical-stage biotechnology company is advancing a pipeline of next-generation immunotherapies and lead product CTX-009, a bispecific antibody targeting DLL4 and VEGF, has demonstrated an “overwhelming efficacy signal” in a Phase 2 trial for biliary tract cancers, the analyst tells investors. The firm’s model based on CTX-009 applies a probability of success of 30% for CTX-009, which the analyst says “may be conservative as a fast pathway to market exists.”

Don't Miss Our Christmas Offers:

Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>

Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App